AU2018279834B2 - Liquid dosage forms to treat cancer - Google Patents

Liquid dosage forms to treat cancer Download PDF

Info

Publication number
AU2018279834B2
AU2018279834B2 AU2018279834A AU2018279834A AU2018279834B2 AU 2018279834 B2 AU2018279834 B2 AU 2018279834B2 AU 2018279834 A AU2018279834 A AU 2018279834A AU 2018279834 A AU2018279834 A AU 2018279834A AU 2018279834 B2 AU2018279834 B2 AU 2018279834B2
Authority
AU
Australia
Prior art keywords
malate
polyethylene glycol
dose
auco
cabozantinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018279834A
Other languages
English (en)
Other versions
AU2018279834A1 (en
Inventor
Steven LACY
Gisela Schwab
Khalid Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2018279834A1 publication Critical patent/AU2018279834A1/en
Application granted granted Critical
Publication of AU2018279834B2 publication Critical patent/AU2018279834B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018279834A 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer Active AU2018279834B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762517736P 2017-06-09 2017-06-09
US62/517,736 2017-06-09
US201762520768P 2017-06-16 2017-06-16
US62/520,768 2017-06-16
PCT/US2018/036703 WO2018227119A1 (en) 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer

Publications (2)

Publication Number Publication Date
AU2018279834A1 AU2018279834A1 (en) 2020-01-16
AU2018279834B2 true AU2018279834B2 (en) 2024-05-23

Family

ID=62779087

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018279834A Active AU2018279834B2 (en) 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer

Country Status (10)

Country Link
US (3) US11504362B2 (https=)
EP (1) EP3634413A1 (https=)
JP (1) JP7249962B2 (https=)
KR (1) KR102647794B1 (https=)
CN (1) CN110678180A (https=)
AU (1) AU2018279834B2 (https=)
CA (1) CA3065560A1 (https=)
MX (1) MX2019014298A (https=)
UA (1) UA126402C2 (https=)
WO (1) WO2018227119A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013020362A2 (pt) * 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
AU2018279834B2 (en) 2017-06-09 2024-05-23 Exelixis, Inc. Liquid dosage forms to treat cancer
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2016019285A1 (en) * 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
PE20131137A1 (es) * 2010-10-29 2013-10-03 Troikaa Pharmaceuticals Ltd Composiciones nasales de vitamina b12
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
EP2758057B1 (en) * 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
JP6464084B2 (ja) 2012-07-27 2019-02-06 イズミ テクノロジー，エルエルシー 排出阻害剤およびこれを用いる治療法
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
UA121655C2 (uk) 2014-04-25 2020-07-10 Екселіксіс, Інк. Спосіб лікування аденокарциноми легень
AU2018279834B2 (en) 2017-06-09 2024-05-23 Exelixis, Inc. Liquid dosage forms to treat cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2016019285A1 (en) * 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
F. M. YAKES ET AL, "Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth", MOLECULAR CANCER THERAPEUTICS, 10,12, 2011, 2298 - 2308, DOI: 10.1158/1535-7163.MCT-11-0264 *
FRAUKE BENTZIEN ET AL: "In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer", THYROID., vol. 23, no. 12, 2013, 1569 - 1577, DOI: 10.1089/thy.2013.0137 *
Q YANG ET AL, "Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation.", BAOJ PHARM SCI, 2015, 1 - 20, URL:http://www.ncbi.nlm.nih.gov/pubmed/25688382 *
R. KURZROCK ET AL, "Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 29, no. 19, 2011, 2660 - 2666,DOI: 10.1200/JCO.2010.32.4145 *
S. LACY ET AL, "Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites", DRUG METABOLISM AND DISPOSITION, v 43, n 8, 2015, 1190-1207, DOI: 10.1124/dmd.115.063610 *

Also Published As

Publication number Publication date
CN110678180A (zh) 2020-01-10
US20200268737A1 (en) 2020-08-27
US12016854B2 (en) 2024-06-25
US20230301978A1 (en) 2023-09-28
US20240307367A1 (en) 2024-09-19
JP2020523317A (ja) 2020-08-06
UA126402C2 (uk) 2022-09-28
US11504362B2 (en) 2022-11-22
BR112019025110A2 (pt) 2020-09-01
KR102647794B1 (ko) 2024-03-15
JP7249962B2 (ja) 2023-03-31
EP3634413A1 (en) 2020-04-15
WO2018227119A1 (en) 2018-12-13
MX2019014298A (es) 2020-02-03
KR20200014903A (ko) 2020-02-11
AU2018279834A1 (en) 2020-01-16
CA3065560A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
AU2018279834B2 (en) Liquid dosage forms to treat cancer
Abel et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
US20240307398A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
US12201610B2 (en) Compositions comprising aticaprant
Lee et al. Bioavailability of modified‐release methylphenidate: influence of high‐fat breakfast when administered intact and when capsule content sprinkled on applesauce
EP4185291B1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
KR20240115224A (ko) 경구용 액상 엔잘루타마이드 조성물
EA043824B1 (ru) Жидкие лекарственные формы для лечения рака
BR112019025110B1 (pt) Composição farmacêutica líquida e seus usos
AU2015360620A1 (en) Treatment of multiple sclerosis with combination of laquinimod and a statin
Aoki et al. Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults
CA2917600A1 (en) Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
Micheal et al. An Evaluation of Relative Bioavailability of Anastrozole Tablets 1 mg in Healthy, Adult, Postmenopausal/Surgically Sterile Indian Female Human Subjects under Fasting Conditions
Wisch Microemulsions: A New Perspective in the Treatment of Paediatric and Geriatric Tuberculosis Patients
Mahesh et al. Pharmacokinetic and Bioequivalence Com-parison Between Lumefantrine Tablets 480mg: an Open Label, Balanced, Random-ized-sequence, Single-dose, Two-period Crossover Study in Healthy Male Volun-teers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)